Gulf Asthma Diagnosis and Management in Adults: Expert Review and Recommendations

Alweqayyan, Adnan; Zaabi, Ashraf Al; Mahboub, Bassam; Alhuraish, Fatma; Hameed, Mansoor; Al‐Ahmad, Mona; Khadadah, Mousa; Lawati, Nabil Al; Behbehani, Nasser; Jabri, Omar Al; Salman, Reyad; Mubaihsi, Saif Al; Raisi, Shadha Al

doi:10.2174/18743064-v16-e2205230

Cited by 5 publications

(3 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Через 3 місяці після впровадження експертних рекомендацій вдалось знизити число призначень монотерапії БАКД на 40 % та на 20 % збільшити число призначень комбінації ІКС-формотерол. І такі зміни, в свою чергу, призвели до збільшення на 55 % числа пацієнтів з контрольованою астмою та до зниження на 35 % числа пацієнтів, що потребували невідкладної допомоги [25][26][27][28][29].…”

Section: огляд літературиunclassified

Global Trends in Therapy of Patients with Bronchial Asthma — a Personalized Approach to Treatment

Зайков¹,

Bogomolov²,

Katilov³

et al. 2023

View full text Add to dashboard Cite

Abstract. Bronchial asthma (BA) refers to those diseases that significantly disrupt the adaptation of patients in society and the family, lead to temporary and permanent loss of working capacity, significant economic costs in many countries of the world. The goals of treating people with ВA in recent years have traditionally remained unchanged and consist in achieving effective symptom control and maintaining a normal level of activity. Despite the availability and accessibility of modern asthma control therapy, lack of control or partial control of ВА is, unfortunately, a common phenomenon among patients with BA. The m ain reason for this phenomenon is the low adherence of people with BA to anti-inflammatory therapy of the disease. Patients with BA often rely on drugs to relieve symptoms, but low adherence to basic therapy and the lack of timely increase in its volume at the initial signs of loss of asthma control sometimes lead to irreversible consequences. The m odern approach to the treatment of BA in adults and adolescents over 12 years of age according to the recommendations of GINA 2022 and NAEPP 2020 is to use a fixed combination of an inhaled corticosteroid with formoterol both for basic therapy and as needed, since it has a rapid and simultaneous anti-inflammatory effect and is effective by alleviating symptoms and reducing the risk of exacerbation. Global climate change is one of the most acute environmental problems facing humanity. The m ain cause of climate change is greenhouse gases produced by human activity. The use of large numbers of short-acting β2-agonist inhalers for the relief of asthma symptoms is one important component of total carbon emissions to the atmosphere, which can be reduced by patients using a fixed combination of inhaled corticosteroid and formoterol as a means of basic and symptomatic therapy.

show abstract

Section: огляд літературиunclassified

Global Trends in Therapy of Patients with Bronchial Asthma — a Personalized Approach to Treatment

Зайков¹,

Bogomolov²,

Katilov³

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Asthma is estimated to affect 357 million people worldwide [12]. At a local level in the Gulf Cooperation Council (GCC) countries, the prevalence of asthma ranges from 4.7% to 32% [13], which translates to 2.9 to 17 million affected.…”

Section: Asthma Burden At a Global And Local Scalementioning

confidence: 99%

Impact of the GINA asthma guidelines 2019 revolution on local asthma guidelines and challenges: special attention to the GCC countries

Allehebi,

AL-Jahdali

2023

Explor Asthma Allergy

View full text Add to dashboard Cite

The Global Initiative for Asthma (GINA) provides the most comprehensive and frequently updated guidelines for the management of asthma. The primary aim of guidelines is to bridge the gap between research and current medical practice by presenting the best available evidence to aid clinical decision-making, thereby improving patient outcomes, quality of care, and cost-effectiveness. Guidelines are particularly useful in situations where scientific evidence is limited, multiple treatment options exist, or there is uncertainty about the best course of action. However, due to variations in healthcare system structures, many countries have developed their own local guidelines for the management of asthma. Adoption of GINA recommendations into local guidelines has been uneven across different countries, with some embracing the changes while others continue to follow older approaches. This review article will explore the impact of the noteworthy changes in GINA guidelines, particularly in the 2019 version, on local guidelines and some of the challenges associated with implementing them.

show abstract

“…In Europe, six biological therapies are available for the management of severe asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab [ 3 ]. However, only four of them (omalizumab, mepolizumab, benralizumab, and dupilumab) are available in the Gulf region including Kuwait [ 4 ]. Omalizumab is the first biologic approved for treating severe allergic asthma associated with high total serum IgE [ 5 ], while the other biologics are used for severe eosinophilic asthma and severe uncontrolled asthma [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Al-Ahmad,

Ali,

Maher

2023

Med Princ Pract

Self Cite

View full text Add to dashboard Cite

Objective: To assess the effectiveness of switching from omalizumab to another biologic therapy for patients with severe asthma and evaluate factors that influenced the decision to switch and determined the optimal time for a good biologic response. Subjects and Methods: A retrospective study of severe asthma patients was conducted at Al-Rashed Allergy, a tertiary center in Kuwait. After meeting the eligibility criteria, patients were divided into two comparative groups; those continuing with omalizumab and those who started with omalizumab but switched to another biologic. Results: One hundred sixteen patients with severe asthma were recruited, and only 33 had access to multiple biological treatments. Approximately 22.4% switched from omalizumab. Male patients with a history of ischemic heart disease, chronic rhinosinusitis, and nasal polyps were more likely to switch if they had higher levels of eosinophils in the sputum. This study showed that every 1% increase in sputum eosinophils doubled the likelihood of a switch. Patients with access to alternative biological options had a much shorter mean duration of omalizumab therapy before switching compared to those with only affordable omalizumab: 4.9±1.5 years versus 8.9±1.3 years (p<0.001). The optimal time to predict the likelihood of a good response was less than 5.5 years, with an AUC of 0.91 and p=0.003. This cutoff point provided a sensitivity and specificity of approximately 89% and 100%, respectively. Conclusion: An early transition to omalizumab, specifically within the first 5 years of treatment, in patients with severe asthma and higher sputum eosinophils may enhance the likelihood of a good response if other biological therapies were available.

show abstract

Gulf Asthma Diagnosis and Management in Adults: Expert Review and Recommendations

Cited by 5 publications

References 131 publications

Global Trends in Therapy of Patients with Bronchial Asthma — a Personalized Approach to Treatment

Global Trends in Therapy of Patients with Bronchial Asthma — a Personalized Approach to Treatment

Impact of the GINA asthma guidelines 2019 revolution on local asthma guidelines and challenges: special attention to the GCC countries

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Contact Info

Product

Resources

About